CEN Biotech INC: directors' dealings · United States · SEC (Form 4)

About CEN Biotech INC

CEN Biotech Inc. is a very small-cap U.S.-investor-tracked name that trades over the counter in the United States, not on the main NYSE or NASDAQ boards. For screening purposes it is often grouped with the broader U.S. listed universe, but investors should treat it as a highly speculative, thinly followed equity with limited public disclosure and a history of corporate restructuring. The company was incorporated in 2013 in Canada and was later separated from Creative Edge Nutrition in a spin-off transaction. Historical SEC filings identify its principal office at 300-3295 Quality Way, Windsor, Ontario, Canada. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1653821/000143774921005883/cenb20201231_10k.htm?utm_source=openai)) Operationally, CEN Biotech has historically described itself as focused on the manufacture, production, and development of LED lighting technology and hemp-based products. The company’s filings indicate that it acquired rights to use a patent related to LED lighting and intended to explore licensing opportunities across horticultural, automotive, industrial, and commercial lighting applications. At the same time, management emphasized hemp-related products intended for industrial, medical, and food uses. As of the latest SEC annual-report information available in the public record used here, the company had not yet generated revenue, had no customers for its LED products, and had not yet developed hemp-based products for sale. That makes the business model highly dependent on execution, financing, and regulatory approvals. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1653821/000143774921005883/cenb20201231_10k.htm?utm_source=openai)) The company’s history is shaped by a significant regulatory setback. CEN Biotech’s application for a license to produce medical marijuana in Canada was formally rejected in 2015 by the Canadian regulator. Following that rejection, the company pivoted away from its original cannabis plan and toward hemp and LED-related initiatives. SEC filings also describe planned use of hemp sourced from the U.S. and Ukraine, along with an intended interest in a Ukrainian operating vehicle for cultivation and processing. In practice, this means the company has operated as a cross-border development story rather than a mature commercial producer, and its prospects remain tied to changing rules on hemp, cannabis derivatives, import/export permissions, and cultivation licenses. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1653821/000143774921005883/cenb20201231_10k.htm?utm_source=openai)) From a market-position standpoint, CEN Biotech remains an early-stage, niche player with no clear evidence of scale, branded product leadership, or meaningful commercial penetration. Its competitive set would include both small hemp businesses and much larger lighting manufacturers, but the filings themselves stress that competition is broad and that the company lacks operating traction. Recent public signals have been limited, but the record does show a 2021 share exchange agreement with Clear Com Media Inc., suggesting efforts to reshape the corporate structure or bring in new strategic assets. For investors in the United States, the key takeaways are the company’s Canadian roots, its OTC trading status, its exposure to the United States and Canada, and the ongoing dependence on insider-filings, restructuring activity, and future financing events as the main sources of new information. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1653821/000143774921009378/cenb20210420_8k.htm?utm_source=openai))